Steinberg modules and Donkin pairs

We prove that in positive characteristic a module with good filtration for a group of type E6 restricts to a module with good filtration for a subgroup of type F4. (Recall that a filtration of a module for a semisimple algebraic group is called good if its layers are dual Weyl modules.) Our result confirms a conjecture of Brundan for one more case. The method relies on the canonical Frobenius splittings of Mathieu. Next we settle the remaining cases, in characteristic not 2, with a computer-aided variation on the old method of Donkin.Comment: 16 pages; proof of Brundan's conjecture adde

Two-dimensional enrichment analysis for mining high-level imaging genetic associations

Enrichment analysis has been widely applied in the genome-wide association studies (GWAS), where gene sets corresponding to biological pathways are examined for significant associations with a phenotype to help increase statistical power and improve biological interpretation. In this work, we expand the scope of enrichment analysis into brain imaging genetics, an emerging field that studies how genetic variation influences brain structure and function measured by neuroimaging quantitative traits (QT). Given the high dimensionality of both imaging and genetic data, we propose to study Imaging Genetic Enrichment Analysis (IGEA), a new enrichment analysis paradigm that jointly considers meaningful gene sets (GS) and brain circuits (BC) and examines whether any given GS-BC pair is enriched in a list of gene-QT findings. Using gene expression data from Allen Human Brain Atlas and imaging genetics data from Alzheimer's Disease Neuroimaging Initiative as test beds, we present an IGEA framework and conduct a proof-of-concept study. This empirical study identifies 12 significant high level two dimensional imaging genetics modules. Many of these modules are relevant to a variety of neurobiological pathways or neurodegenerative diseases, showing the promise of the proposal framework for providing insight into the mechanism of complex diseases

Production of bioplastic using Jackfruit perianth

Overuse of plastics around the world has made them one of the key environmental concerns today. Disposal of plastic waste in landfills has serious environmental impacts due to its non-biodegradable nature. Agricultural waste, particularly plant materials containing starch gains attraction for its role in the production of alternative biodegradable materials with good tensile strength and other mechanical properties. The present work focuses on production of biodegradable bioplastic using perianth of Jackfruit [Artocarpus heterophyllus Lam. (Moraceae)], which otherwise goes as agro waste. Certain plasticizers are also used to improve the raw materials properties and it was subjected to various tests, to study its mechanical and chemical properties. The sample was characterized using Fourier transform Infrared spectroscopy (FTIR) and tensile strength was also checked. It was subjected to various resistance tests such as water resistance, alcohol resistance, flammability, alkali and acid resistance and it was confirmed that the bioplastic produced from Jack fruit perianth is a good option to normal plastics

Stringent constraints on the scalar K pi form factor from analyticity, unitarity and low-energy theorems

We investigate the scalar K pi form factor at low energies by the method of unitarity bounds adapted so as to include information on the phase and modulus along the elastic region of the unitarity cut. Using at input the values of the form factor at t=0 and the Callan-Treiman point, we obtain stringent constraints on the slope and curvature parameters of the Taylor expansion at the origin. Also, we predict a quite narrow range for the higher order ChPT corrections at the second Callan-Treiman point.Comment: 5 pages latex, uses EPJ style files, 3 figures, replaced with version accepted by EPJ

Remarks on lines and minimal rational curves

We determine all of lines in the moduli space $M$ of stable bundles for arbitrary rank and degree. A further application of minimal rational curves is also given in last section

Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with Juvenile Idiopathic Arthritis

Purpose To investigate the cost effectiveness of adalimumab in combination with methotrexate, compared with methotrexate alone, for the management of uveitis associated with juvenile idiopathic arthritis (JIA). Design A cost-utility analysis based on a clinical trial and decision analytic model. Participants Children and adolescents 2 to 18 years of age with persistently active uveitis associated with JIA, despite optimized methotrexate treatment for at least 12 weeks. Methods The SYCAMORE (Randomised controlled trial of the clinical effectiveness, SafetY and Cost effectiveness of Adalimumab in combination with MethOtRExate for the treatment of juvenile idiopathic arthritis associated uveitis) trial (identifier, ISRCTN10065623) of methotrexate (up to 25 mg weekly) with or without fortnightly administered adalimumab (20 or 40 mg, according to body weight) provided data on resource use (based on patient self-report and electronic records) and health utilities (from the Health Utilities Index questionnaire). Surgical event rates and long-term outcomes were based on data from a 10-year longitudinal cohort. A Markov model was used to extrapolate the effects of treatment based on visual impairment. Main Outcome Measures Medical costs to the National Health Service in the United Kingdom, utility of defined health states, quality-adjusted life-years (QALYs), and incremental cost per QALY. Results Adalimumab in combination with methotrexate resulted in additional costs of £39 316, with a 0.30 QALY gain compared with methotrexate alone, resulting in an incremental cost-effectiveness ratio of £129 025 per QALY gained. The probability of cost effectiveness at a threshold of £30 000 per QALY was less than 1%. Based on a threshold analysis, a price reduction of 84% would be necessary for adalimumab to be cost effective. Conclusions Adalimumab is clinically effective in uveitis associated with JIA; however, its cost effectiveness is not demonstrated compared with methotrexate alone in the United Kingdom setting